Literature DB >> 19427557

The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.

Christina S Kong1, Balasubramanian Narasimhan, Hongbin Cao, Shirley Kwok, Julianna P Erickson, Albert Koong, Nader Pourmand, Quynh-Thu Le.   

Abstract

PURPOSE: To evaluate the relationship between human papillomavirus (HPV) status and known prognostic makers for head and neck cancers including tumor hypoxia, epidermal growth factor receptor (EGFR) expression and intratumoral T-cell levels and to determine the prognostic impact of these markers by HPV status. METHODS AND MATERIALS: HPV status in 82 evaluable head and neck squamous cell carcinomas patients was determined by pyrosequencing and related to p16(INK4a) staining and treatment outcomes. It was correlated with tumor hypoxia (tumor pO(2) and carbonic anhydrase [CAIX] staining), EGFR status, and intratumoral lymphocyte expression (CD3 staining).
RESULTS: Forty-four percent of evaluable tumors had strong HPV signal by pyrosequencing. There was a significant relationship between strong HPV signal and p16(INK4a) staining as well as oropharynx location. The strong HPV signal group fared significantly better than others, both in time to progression (TTP, p = 0.008) and overall survival (OS, p = 0.004) for all patients and for the oropharyngeal subset. Positive p16(INK4a) staining was associated with better TTP (p = 0.014) and OS (p = 0.00002). There was no relationship between HPV status and tumor pO(2) or CAIX staining. However, HPV status correlated inversely with EGFR reactivity (p = 0.0006) and directly with CD3(+) T-lymphocyte level (p = 0.03). Whereas CAIX and EGFR overexpression were negative prognostic factors regardless of HPV status, CD3(+) T-cell levels was prognostic only in HPV(-) tumors.
CONCLUSION: HPV status was a prognostic factor for progression and survival. It correlated inversely with EGFR expression and directly with T-cell infiltration. The prognostic effect of CAIX and EGFR expression was not influenced by HPV status, whereas intratumoral T-cell levels was significant only for HPV(-) tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427557      PMCID: PMC2768774          DOI: 10.1016/j.ijrobp.2009.02.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  41 in total

1.  Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.

Authors:  R J Bova; D I Quinn; J S Nankervis; I E Cole; B F Sheridan; M J Jensen; G J Morgan; C J Hughes; R L Sutherland
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

2.  Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Johan W Molling; Jacqueline A E Langius; Johannes A Langendijk; C René Leemans; Hetty J Bontkes; Hans J J van der Vliet; B Mary E von Blomberg; Rik J Scheper; Alfons J M van den Eertwegh
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

3.  Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.

Authors:  Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

4.  Case-control study of human papillomavirus and oropharyngeal cancer.

Authors:  Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

5.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Authors:  Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

6.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.

Authors:  Bhavna Kumar; Kitrina G Cordell; Julia S Lee; Francis P Worden; Mark E Prince; Huong H Tran; Gregory T Wolf; Susan G Urba; Douglas B Chepeha; Theodoros N Teknos; Avraham Eisbruch; Christina I Tsien; Jeremy M G Taylor; Nisha J D'Silva; Kun Yang; David M Kurnit; Joshua A Bauer; Carol R Bradford; Thomas E Carey
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

7.  Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.

Authors:  Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

8.  Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.

Authors:  Quynh-Thu Le; Christina Kong; Phillip W Lavori; Ken O'byrne; Janine T Erler; Xin Huang; Yijun Chen; Hongbin Cao; Robert Tibshirani; Nic Denko; Amato J Giaccia; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-01       Impact factor: 7.038

Review 9.  Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.

Authors:  Camille C R Ragin; Emanuela Taioli
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

10.  Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.

Authors:  Bhavna Kumar; Kitrina G Cordell; Julia S Lee; Mark E Prince; Huong H Tran; Gregory T Wolf; Susan G Urba; Francis P Worden; Douglas B Chepeha; Theodoros N Teknos; Avraham Eisbruch; Christina I Tsien; Jeremy M G Taylor; Nisha J D'Silva; Kun Yang; David M Kurnit; Carol R Bradford; Thomas E Carey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007       Impact factor: 7.038

View more
  89 in total

Review 1.  Next-generation and whole-genome sequencing in the diagnostic clinical microbiology laboratory.

Authors:  W M Dunne; L F Westblade; B Ford
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-08       Impact factor: 3.267

2.  A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.

Authors:  Jill Gilbert; Michelle A Rudek; Michaela J Higgins; Ming Zhao; Sara Bienvenu; Nancy Tsottles; Muhammad A Chaudhry; Richard Wahl; Arlene Forastiere; Maura Gillison
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

3.  Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.

Authors:  Chad Tang; James D Murphy; Brian Khong; Trang H La; Christina Kong; Nancy J Fischbein; A Dimitrios Colevas; Andrei H Iagaru; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-21       Impact factor: 7.038

Review 4.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

5.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

6.  Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions.

Authors:  Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri
Journal:  Otolaryngol Head Neck Surg       Date:  2014-05-08       Impact factor: 3.497

7.  Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.

Authors:  Jessica Ley; Paul Mehan; Tanya M Wildes; Wade Thorstad; Hiram A Gay; Loren Michel; Brian Nussenbaum; Kathryn Trinkaus; Douglas Adkins
Journal:  Oncology       Date:  2013-11-06       Impact factor: 2.935

8.  Diffuse optical measurements of head and neck tumor hemodynamics for early prediction of chemoradiation therapy outcomes.

Authors:  Lixin Dong; Mahesh Kudrimoti; Daniel Irwin; Li Chen; Sameera Kumar; Yu Shang; Chong Huang; Ellis L Johnson; Scott D Stevens; Brent J Shelton; Guoqiang Yu
Journal:  J Biomed Opt       Date:  2016-08-01       Impact factor: 3.170

9.  Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer.

Authors:  Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

10.  E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer.

Authors:  Angela Hong; Xiaoying Zhang; Deanna Jones; Mei Zhang; C Soon Lee; J Guy Lyons; Anne-Sophie Veillard; Barbara Rose
Journal:  Cancer Biol Ther       Date:  2015-11-17       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.